Key result
Review highlights heart transplantation and MCS outcomes and challenges for chemotherapy-induced cardiomyopathy in cancer survivors.
Why the study?
As cancer survival improves, patients with chemotherapy-induced cardiomyopathy are expected to increasingly require advanced therapies for end-stage heart failure, but distinct outcomes and challenges in this population are not well characterized.
This review highlights the characteristics, challenges, and outcomes of advanced heart failure therapies, such as heart transplantation and mechanical circulatory support, in cancer survivors with chemotherapy-induced cardiomyopathy.
Anthracycline CCMP may increase advanced HF therapy referrals; leaves open dedicated outcome data for LVAD and transplantation.
Chemotherapy-induced cardiomyopathy (CCMP) is a significant cause of morbidity and mortality. Compared to cardiomyopathy due to other causes, anthracycline-induced cardiomyopathy is associated with a worse survival. As cancer survival improves, patients with CCMP can be expected to comprise a significant proportion of patients who may require advanced therapies such as inotropic support, cardiac transplantation, or left ventricular assist device (LVAD). Distinct outcomes related to advanced therapies for end-stage heart failure in this patient population may arise due to unique demographic characteristics and comorbidities. We review recent literature regarding the characteristics of patients who have survived cancer undergoing orthotopic heart transplantation and mechanical circulatory support for end-stage heart failure. The challenges and outcomes of advanced therapies for heart failure related specifically to anthracycline-induced cardiomyopathy are emphasized.
No takes yet. Share an insight, caveat, or question.
Ghosh et al. (2015) conducted a review in Chemotherapy-induced cardiomyopathy. Orthotopic heart transplantation and mechanical circulatory support was evaluated. This review highlights challenges and outcomes of heart transplantation and mechanical circulatory support for end-stage heart failure in cancer survivors with chemotherapy-induced cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: